5 December - 6 December 2016

Protein-Protein Interactions 2016

Organised by:

 SCI's Fine Chemicals Group and RSC's BMCS in association with PPI-Net

SCI, London

Registration Closed

This event is no longer available for registration.

Synopsis

Virtually all vital cellular processes are controlled by protein-protein interactions (PPIs) including gene expression, proliferation, intracellular communication and apoptosis. Thus, understanding and manipulating PPIs represents a key objective in being able to understand healthy and disease biology. Achieving this goal will lead to probes of cell signalling pathways or, systems biology and next generation molecular therapeutics. However, to date, only a few PPIs have been the subject of a drug discovery initiative by the pharmaceutical industry.

Owing to the potential opportunities that being able to modulate PPIs would bring, the past decade has seen this field gain increasing scientific interest, and stimulated significant academic and industrial innovation. This meeting will address recent advances in the characterisation and identification of new PPI inhibitors. Topics will include: in silico assessment of PPI druggability, assay screening technologies for PPIs, structural biology approaches and fragment-based drug design. Speakers from industry and academia will describe strategies for addressing these challenges whilst showcasing the opportunity for creativity and innovation.


Attendees

The event is aimed at all scientists (students, post-docs, academics, industrialists) engaged in PPI research, alongside those interested in finding out more about this topic. The meeting programme will appeal to chemists, biologists and the wider drug-discovery community.

Full programme details will be available in due course. Download the event flyer.


Programme

Day 1 - 5th December 2016

Event Schedule
08:45
Registration and refreshments
09:20
Opening remarks
09:30
Plenary talk Cooperativity in multiprotein assemblies over space and time: implications for cell signalling and druggability Sir Tom Blundell, University of Cambridge, UK
10:30
Targeting protein-protein interactions in the brain Asst Prof Michael Maric, University of Copenhagen, Denmark
11:00
Refreshments, poster and exhibition viewing
11:30
Targeting aggregating proteins in drug discovery Dr Lewis Vidler, Eli Lilly & Co, UK
12:00
Using the kinase ATP binding site to inhibit PPIs Prof Richard Bayliss, University of Leeds, UK
12:30
Lunch, poster and exhibition viewing
13:30
Folded fragment approach for target-directed development of protein-protein interaction inhibitors Prof Dr Mr Tamás Martinek, University of Szeged, Hungary
14:00
Characterising PPI interfaces and assessing druggability using mixed-solvent simulations Dr Davide Branduardi, Schrodinger, UK
14:30
Discovery and characterisation of small molecule fragments that bind and inhibit the ubiquitin specific protease 7 (USP7) Dr Paola Di Lello, Genentech, USA
15:00
Refreshments, poster and exhibition viewing
15:30
Inhibiting PPIs: a structural biologists perspective Dr Thomas Edwards, University of Leeds, UK
16:00
Flash poster presentations
16:30
Wine reception and poster viewing
19:00
Conference dinner

Day 2 - 6th December 2016

Event Schedule
09:30
Plenary talk Discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design Prof Steve Fesik, Vanderbilt University Medical Centre, USA
10:30
ProMs: A construction kit for small-molecule inhibitors of protein-protein interactions involving proline-rich motifs Prof Dr Hans-Guenther Schmalz, University of Cologne, Germany
11:00
Refreshments, poster and exhibition viewing
11:30
Highly potent cell-penetrant inhibitors of the KEAP1- NRF2 protein-protein interaction via x-ray fragment screening Dr Tom Heightman, Astex Pharmaceuticals, UK
12:00
The discovery of NVP-HDM201: identification of a next generation HDM2 inhibitor with superior characteristics Dr Andrea Vaupel, Novartis, Switzerland
12:30
Lunch, poster and exhibition viewing
1330
Protein-fragment complementation and semi-rational design: engineering specific antagonists of proteinprotein interactions Dr Jody Mason, University of Bath, UK
14:00
Small molecule inhibition of PCSK9-LDL receptor binding: a summit too high? Dr Kim McClure, Pfizer, USA
14:30
Targeting the SCL-LMO2 interaction: a structure-guided approach to T-ALL drug discovery Dr Leanne Harris, University of Sussex, UK
15:00
Refreshments, poster and exhibition viewing
15:30
Inhibition of FGFR2 oncogenic activity by its C-terminal tail Dr Chi-Chuan Lin, University of Leeds, UK
16:00
Antibody-enabled small molecule drug discovery Dr Alastair Lawson, UCB, UK
16:30
Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation Dr Jon Winter-Holt, AstraZeneca, UK
17:00
Closing remarks
17:30
Lunch

Venue and Contact

14/15 Belgrave Square 
London 
SW1X 8PS


A location map can be found here.

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Fees
GB£200 . . . . . . . . . SCI/RSC Member
GB£40. . . . . . . . . . .SCI/RSC Student Member
GB£120. . . . . . . . . .SCI/RSC Subsidised Member
GB£260 . . . . . . . . . Non Member

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Booking Process
For booking terms and conditions click here.
CPD Info
SCI Members can claim CPD points for attending this conference.
Partners

Exhibitors

Sponsors

Additional Info

Sponsorship

To enquire about sponsorship opportunities, please contact clarice.williams@soci.org for further information and costs.

Conference Dinner - SOLD OUT

A Conference Dinner will take place on the evening of Monday 5 December. A limited number of tickets are available for GB£60. 
To book your place, please select this option when registering to attend the event or contact the SCI Conference Team.